Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Novel Predictors of Transplant Rejection Determined by Peripheral Blood Gene-Expression Profiling

Description:

Docket #  Q3426

 

 

Problem

There are approximately 2,300 heart transplants performed yearly in the United States that require frequent endomyocardial biopsies to monitor for allograft rejection.  These procedures are invasive, cause discomfort for the patient, have a risk of complications and are costly.

 

Solution

Researchers at the University of Pennsylvania have identified a gene panel that can be used to predict graft rejection in cardiac transplant recipients using a patient’s peripheral blood samples. The current technology has been validated using a total of 409 samples collected from patients with endomyocardial biopsies. Detection of rejection before the onset of cardiac dysfunction is a major concern in the care of cardiac transplant patients. 

Compared to endomyocardial biopsy, this technique uses whole blood samples and does not require the isolation of peripheral blood mononuclear cells reducing time. Additionally the technique can be used to rapidly identify candidate recipients for successful organ transplantation, thereby maximizing the benefit from the organ donor supply.

 

Advantages

• non-invasive test

• whole blood samples 

• maximize benefit for the organ donor supply

 

Inventor

Jonathan Epstein, MD

 

 

State of Development

validation on clinical samples performed. Prospective studies need to be performed

 

Intellectual Property

US Patent  US 8,053,182

 

Desired partnerships

• License

 

Download PDF

 


Patent Information:
Category(s):
Diagnostics
For Information, Contact:
Viviane Martin
Director, PSOM Licensing Group
University of Pennsylvania
martinv@upenn.edu
Inventors:
Jonathan Epstein
Keywords:
Cardiovascular
Diagnostics
Genomics
Transplantation